Lung cancer can be one of the most difficult cancers to treat successfully, in part because it can quickly become resistant to anti-cancer drugs.
 Dr. Karen Reckamp and her City of Hope team are combining proven drugs in new ways to slow or even stop deadly lung cancer. |
The work you are making possible at City of Hope is uncovering new solutions to this problem, offering a brighter future for lung cancer patients.
Karen Reckamp, M.D., leads a City of Hope team investigating a promising new strategy that combines two existing types of drugs to target a key protein in lung cancer cells.
One type of drug, known as an EGFR inhibitor, is already used to treat lung cancer, although it is only effective in about 10% of patients. When combined with another type of drug known as a COX-2 inhibitor, however, early testing showed the EGFR inhibitor seems to become much more effective. Blocking that that key protein slows or even stops the spread of cancer.
Dr. Reckamp and her team are now conducting phase II trials with this combination of drugs. This is just one more example of how your generosity makes possible innovative research that is finding new ways to treat, and ultimately, defeat cancer at City of Hope.
